Skip to main content

Creative Biolabs: Cranking Up Gene Therapy Games with Circular RNA Technology

By: Get News
Creative Biolabs is flipping the script on gene therapy with cutting-edge circular RNA tech, giving researchers the tools to tackle tough diseases.

New York, USA - August 29, 2024 - Circular RNA (circRNA) has gained attention for its role in various cellular processes, with dysregulation implicated in numerous diseases, which are attractive candidates for therapeutic development because of their greater stability and resistance to exonucleases owing to the covalently closed-loop structures. Creative Biolabs recognizes the potential of circRNA and has developed a suite of services to support researchers in their quest to harness these molecules for therapeutic purposes, from circular RNA synthesis to analysis and reporter circular RNA products.

"Our mission is to empower researchers with the best-in-class resources to unlock the full potential of circRNA in gene therapy," said a scientist from Creative Biolabs. "We understand the complexities of circRNA research, and our services are designed to streamline the process, whether it's the custom synthesis of circRNAs tailored to specific needs or the in-depth analysis required to understand their function and therapeutic potential."

One of the key offerings is their custom circRNA synthesis service. Recognizing that each research project is unique, Creative Biolabs tailors each project to meet the specific requirements-whether it's synthesizing circRNAs for gain-of-function studies or creating plasmids for circRNA expression-their scientist team ensures to provide high-quality, highly stable circRNAs that are ready to be integrated into the designated experimental workflows.

Moreover, Creative Biolabs offers comprehensive circRNA analysis services to help researchers understand the role of these molecules in disease. From sequence verification to expression profiling, their analytical capabilities provide deep insights into the behavior and function of circRNAs, returning data crucial for developing effective circRNA-based therapies, as it allows scientists to pinpoint the exact mechanisms by which these molecules influence cellular processes.

"Our analytical services include circRNA sequencing, expression profiling, and functional studies, to map out a complete picture of how these molecules contribute to health and disease. This deep level of analysis is core for identifying potential therapeutic targets and developing effective gene therapies," the scientist elaborated.

Additionally, Creative Biolabs provides reporter circRNA products designed to monitor and evaluate circRNA activity within cells, which are designed to facilitate the study of researchers aiming to validate their circRNA constructs and assess their functionality in real-time. By incorporating reporter genes into circRNAs, researchers can gain a clearer understanding of how their engineered circRNAs behave in various cellular environments, paving the way for more accurate and effective therapeutic interventions.

"The rapid pace of circRNA research underscores the need for reliable, high-quality tools and services. We at Creative Biolabs are committed to supporting the scientific community by delivering innovative solutions that drive progress in gene therapy," the scientist remarked.

For more information about Creative Biolabs' services and products, visit their website at https://www.creative-biolabs.com/gene-therapy.

About

Creative Biolabs is a leading biotechnology company specializing in custom services to fuel the research and development of gene therapy, immunotherapy, and other therapeutic attempts.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.